Insilico Medicine lists on Hong Kong Stock Exchange, showing AI drug discovery momentum with 2025’s largest Hong Kong biotech IPO - EurekAlert!
Insilico Medicine and Taigen achieves license agreement to develop and commercialize AI-driven PHD inhibitor for anemia of Chronic Kidney Disease (CKD) - EurekAlert!
Insilico Medicine unveils winter edition of Pharma.AI, accelerating the path to pharmaceutical superintelligence - EurekAlert!
Insilico Medicine and Atossa Therapeutics publish AI-driven study in Nature's Scientific Reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma - EurekAlert!
Join Insilico Medicine at NeurIPS 2025: Unveiling generative AI breakthroughs revolutionizing drug discovery and development - EurekAlert!
Meet us at PFF Summit 2025 | Insilico Medicine to showcase generative AI platform and introduce their latest AI-driven Pulmonary Fibrosis clinical research at PFF Summit 2025 in Chicago, IL - EurekAlert!
Insilico Medicine named a 2025 BostInno Fire Awards honoree - EurekAlert!
Insilico Medicine CEO Alex Zhavoronkov to speak on longevity and AI in healthcare at Fortune Global Forum in Riyadh - EurekAlert!
Showcasing gen-AI breakthroughs, Insilico Medicine presents fall edition of Pharma.AI quarterly launch - EurekAlert!
Insilico Medicine, Mabwell Bioscience, and ChemExpress forging ahead with ADC innovation through strategic collaboration - EurekAlert!
Towards pharmaceutical super intelligence: During BioHK 2025, Insilico Medicine gathers industry leaders to shape the future of AI in healthcare - EurekAlert!
Transforming Parkinson’s disease treatment, Insilico Medicine announces IND-enabling completion for AI-empowered oral NLRP3 inhibitor ISM8969 - EurekAlert!
Pharma.ai summer 2025 updates: Join Insilico Medicine on July 10 for the future of AI-empowered medical research boost - EurekAlert!
JMC | Insilico Medicine publishes AI-driven innovative design strategy for highly selective FGFR2/3 inhibitors - EurekAlert!
Insilico Medicine completes first-in-patient dosing of ISM3412, the novel MAT2A inhibitor for the treatment of locally advanced/metastatic solid tumors - EurekAlert!
Insilico Medicine completes oversubscribed Series E, bringing total funding around $123 million - EurekAlert!
Insilico Medicine announces Nature Medicine publication of Phase IIa results evaluating rentosertib, the novel TNIK inhibitor for idiopathic pulmonary fibrosis (IPF) discovered and designed with a pioneering AI approach - EurekAlert!
Insilico Medicine and collaborator announce discovery of potent WDR5-MYC interaction inhibitors through generative AI platform - EurekAlert!
Pharma.AI Day 2025: Register now! Insilico Medicine to unveil gen-AI platform quarterly updates on April 24 - EurekAlert!
Booth #5A14｜Meet Insilico Medicine at Abu Dhabi Global Health Week - EurekAlert!
